Akero Therapeutics Inc
AKRO54.140USD
+0.100+0.19%
Fechamento 11/10, 16:00（ET）Cotações atrasadas em 15 min
4.34BValor de mercado
PerdaP/L TTM
Mais detalhes de Akero Therapeutics Inc Empresa
Akero Therapeutics, Inc. is a clinical-stage company. The Company is developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH), a disease without any approved therapies. Efruxifermin (EFX), is its lead product candidate for MASH, which is being evaluated in the ongoing phase IIb SYMMETRY, phase III SYNCHRONY Histology, and phase III SYNCHRONY real-world studies. The phase III SYNCHRONY program builds on the results of two phase IIb clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. EFX is designed to offer convenient once-weekly dosing.
Informações de Akero Therapeutics Inc
Código da empresaAKRO
Nome da EmpresaAkero Therapeutics Inc
Data de listagemJun 20, 2019
CEODr. Andrew Cheng, M.D., Ph.D.
Número de funcionários63
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 20
Endereço601 Gateway Boulevard, Suite 350
CidadeSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94080
Telefone16504876488
Sitehttps://akerotx.com/
Código da empresaAKRO
Data de listagemJun 20, 2019
CEODr. Andrew Cheng, M.D., Ph.D.
Executivos da empresa Akero Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
393.38K
+51.69%
Dr. Jonathan Young, J.D., Ph.D.
Dr. Jonathan Young, J.D., Ph.D.
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
217.63K
+13.41%
Ms. Catriona Yale
Ms. Catriona Yale
Chief Development Officer
Chief Development Officer
35.53K
+30.32%
Mr. Patrick Lamy
Mr. Patrick Lamy
Senior Vice President - Commercial Strategy
Senior Vice President - Commercial Strategy
32.93K
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Yuan Xu, Ph.D.
Dr. Yuan Xu, Ph.D.
Independent Director
Independent Director
--
-100.00%
Dr. Graham L. Walmsley, M.D., Ph.D.
Dr. Graham L. Walmsley, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Scott A. Gangloff
Mr. Scott A. Gangloff
Chief Technology Officer
Chief Technology Officer
--
--
Dr. Judy Chou, Ph.D.
Dr. Judy Chou, Ph.D.
Independent Director
Independent Director
--
--
Dr. Seth L. Harrison, M.D.
Dr. Seth L. Harrison, M.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
393.38K
+51.69%
Dr. Jonathan Young, J.D., Ph.D.
Dr. Jonathan Young, J.D., Ph.D.
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
217.63K
+13.41%
Ms. Catriona Yale
Ms. Catriona Yale
Chief Development Officer
Chief Development Officer
35.53K
+30.32%
Mr. Patrick Lamy
Mr. Patrick Lamy
Senior Vice President - Commercial Strategy
Senior Vice President - Commercial Strategy
32.93K
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Yuan Xu, Ph.D.
Dr. Yuan Xu, Ph.D.
Independent Director
Independent Director
--
-100.00%
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qua, 3 de set
Atualizado em: qua, 3 de set
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Janus Henderson Investors
8.19%
General Atlantic LLC
6.97%
RTW Investments L.P.
6.65%
BlackRock Institutional Trust Company, N.A.
6.15%
The Vanguard Group, Inc.
5.48%
Outro
66.56%
Investidores
Investidores
Proporção
Janus Henderson Investors
8.19%
General Atlantic LLC
6.97%
RTW Investments L.P.
6.65%
BlackRock Institutional Trust Company, N.A.
6.15%
The Vanguard Group, Inc.
5.48%
Outro
66.56%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
47.16%
Investment Advisor
33.05%
Hedge Fund
22.49%
Private Equity
9.32%
Research Firm
3.22%
Venture Capital
3.01%
Individual Investor
1.29%
Foundation
0.41%
Pension Fund
0.32%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
509
95.38M
115.92%
-917.24K
2025Q2
491
87.62M
109.91%
-627.50K
2025Q1
495
89.01M
111.79%
+1.41M
2024Q4
453
76.50M
96.29%
-13.73M
2024Q3
445
77.37M
111.97%
-14.20M
2024Q2
428
76.12M
110.88%
-16.59M
2024Q1
421
77.80M
117.45%
+1.74M
2023Q4
401
63.49M
113.86%
-5.60M
2023Q3
387
61.40M
112.62%
-2.96M
2023Q2
363
60.44M
111.44%
+4.13M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Janus Henderson Investors
6.74M
8.42%
-330.09K
-4.67%
Jun 30, 2025
General Atlantic LLC
5.73M
7.17%
+500.00K
+9.55%
Jun 30, 2025
RTW Investments L.P.
5.48M
6.85%
-1.94M
-26.17%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.06M
6.33%
-421.07K
-7.68%
Jun 30, 2025
The Vanguard Group, Inc.
4.52M
5.65%
+297.51K
+7.05%
Jun 30, 2025
T. Rowe Price Associates, Inc.
4.42M
5.53%
-310.43K
-6.56%
Jun 30, 2025
Deep Track Capital LP
3.04M
3.8%
-167.67K
-5.22%
Jun 30, 2025
Avoro Capital Advisors LLC
3.50M
4.38%
+3.50M
--
Jun 30, 2025
Wellington Management Company, LLP
3.41M
4.26%
-2.53M
-42.56%
Jun 30, 2025
State Street Investment Management (US)
2.75M
3.43%
+250.82K
+10.05%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: qui, 6 de nov
Atualizado em: qui, 6 de nov
Nome
Proporção
Simplify Propel Opportunities ETF
10.44%
ALPS Medical Breakthroughs ETF
2.19%
SPDR S&P Biotech ETF
1.64%
AltShares Merger Arbitrage ETF
1.63%
Direxion Daily S&P Biotech Bull 3X Shares
0.86%
Virtus LifeSci Biotech Clinical Trials ETF
0.64%
Tema Heart & Health ETF
0.63%
ProShares Ultra Nasdaq Biotechnology
0.39%
Invesco Nasdaq Biotechnology ETF
0.38%
iShares Biotechnology ETF
0.32%
Ver Mais
Simplify Propel Opportunities ETF
Proporção10.44%
ALPS Medical Breakthroughs ETF
Proporção2.19%
SPDR S&P Biotech ETF
Proporção1.64%
AltShares Merger Arbitrage ETF
Proporção1.63%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.86%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.64%
Tema Heart & Health ETF
Proporção0.63%
ProShares Ultra Nasdaq Biotechnology
Proporção0.39%
Invesco Nasdaq Biotechnology ETF
Proporção0.38%
iShares Biotechnology ETF
Proporção0.32%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
